Wall Street Zen Upgrades Kalaris Therapeutics (NASDAQ:KLRS) to “Hold”

Kalaris Therapeutics (NASDAQ:KLRS) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

A number of other research analysts have also recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kalaris Therapeutics in a report on Monday, December 29th. Citizens Jmp assumed coverage on Kalaris Therapeutics in a research report on Monday, November 3rd. They set a “market outperform” rating and a $20.00 target price on the stock. Chardan Capital initiated coverage on Kalaris Therapeutics in a research note on Tuesday, December 23rd. They issued a “buy” rating and a $19.00 price target for the company. Finally, Citigroup reaffirmed an “outperform” rating on shares of Kalaris Therapeutics in a report on Thursday, December 18th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $14.00.

Kalaris Therapeutics Price Performance

Shares of NASDAQ KLRS opened at $10.00 on Friday. The stock has a market capitalization of $187 million, a price-to-earnings ratio of -2.65 and a beta of -0.09. The firm’s 50 day simple moving average is $9.22 and its 200-day simple moving average is $6.43. Kalaris Therapeutics has a 12 month low of $2.14 and a 12 month high of $12.90.

Insiders Place Their Bets

In other news, Director Srinivas Akkaraju acquired 479,847 shares of the stock in a transaction that occurred on Thursday, December 18th. The shares were bought at an average cost of $10.42 per share, for a total transaction of $5,000,005.74. Following the acquisition, the director owned 1,979,847 shares in the company, valued at approximately $20,630,005.74. This represents a 31.99% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 74.99% of the company’s stock.

Hedge Funds Weigh In On Kalaris Therapeutics

Hedge funds have recently made changes to their positions in the company. XTX Topco Ltd acquired a new stake in shares of Kalaris Therapeutics in the fourth quarter worth approximately $92,000. Ikarian Capital LLC purchased a new position in Kalaris Therapeutics in the 4th quarter valued at $3,038,000. RTW Investments LP purchased a new position in Kalaris Therapeutics in the 4th quarter valued at $10,972,000. Boothbay Fund Management LLC acquired a new stake in Kalaris Therapeutics during the 4th quarter worth $779,000. Finally, 683 Capital Management LLC purchased a new stake in shares of Kalaris Therapeutics during the fourth quarter worth $680,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.